INTRODUCTION
============

MicroRNAs (miRNAs) are the most studied and best characterized molecules in the class of small regulatory non-coding RNAs ([@B3]). They are involved in several important biological processes and functions through post-transcriptional regulation of the expression of messenger RNAs (mRNAs), and their dysregulation is often cause or consequence of a variety of diseases, such as cancer and neurodegenerative disorders ([@B10]; [@B15]). Cellular miRNAs can be packaged into different carriers and exported to recipient cells or released in small vesicles during apoptosis ([@B5]; [@B28]). The discovery of extracellular miRNAs in biological fluids has started a new exciting field of research. Circulating miRNAs are now considered useful markers of disease conditions and functional mediators of several biological processes in a novel form of cell-to-cell communication. A novel useful resource is the database miRandola, which provides users with a comprehensive manually curated classification of extracellular circulating miRNAs ([@B67]).

Viruses encode their own sets of miRNAs. Evidence shows that these miRNAs can act as self-regulators of viral gene expression and/or control host cell pathways through silencing of their nodes ([@B42]). Some viruses can exploit extracellular particles for the initiation and progression of the infection and recent evidence indicates that viruses can export and deliver functional miRNAs through vesicles ([@B60]). This discovery reveals a new layer in the infectious mechanism used by viruses to maintain their latency and control crucial host pathways whose targeting is likely beneficial to the virus.

In this mini review we summarize the current knowledge about circulating miRNAs and their potential regulatory functions, with particular emphasis on extracellular viral miRNAs. We report the promising results of the most recent studies and provide a few examples of computational prediction of viral miRNA function.

CURRENT KNOWLEDGE
=================

CIRCULATING miRNAs ARE FUNCTIONAL IN RECIPIENT CELLS AND CONSTITUTE USEFUL BIOMARKERS FOR VARIOUS CONDITIONS
------------------------------------------------------------------------------------------------------------

Extracellular miRNAs have been recently identified stable in most biological fluids, including blood, urine, saliva, semen, cerebrospinal fluid, and breast milk ([@B53]; [@B26]; [@B83]; [@B1]; [@B20]; [@B92]). Evidence shows that they may be selectively packaged into different kinds of carriers, such as membrane-derived vesicles, lipoproteins, and ribonucleoprotein complexes, which protect them from degradation and export them to recipient cells where they exert their regulatory functions. Particularly, exosomes and microparticles (MPs) are two distinct classes of small membrane-enclosed vesicles released from cells, differing in size, biogenesis, and secretory mechanisms ([@B5]). Exosomes are produced by the inward budding of the limiting membrane of multivesicular bodies (MVBs). They are smaller than MPs, which are instead formed by the outward budding and blebbing of the plasma membrane. Small sealed membrane vesicles that are produced from cells during apoptosis, called apoptotic bodies, can also transport specific sets of miRNAs. Extracellular miRNAs have also been found in high-density lipoproteins (HDL) and low-density lipoproteins (LDL), and bound to Argonaute 2 (AGO2) and other ribonucleoproteins, both in and out of membrane-derived vesicles ([@B2]; [@B80]; [@B82]; [@B65]). Viral surface antigen particles may also carry specific miRNAs, as in the case of hepatitis B surface antigen particles which contain hepatocellular miRNAs bound to AGO2 ([@B57]).

MicroRNA profiles of extracellular carriers show distinct sets of miRNAs than their parent cell-type, thus suggesting that some miRNAs might be transcribed only to be exported and not retained in the parent cell ([@B58]; [@B62]). Selective packaging of miRNAs into vesicles is probably related to the specific biological functions of the secreted miRNAs.

Circulating miRNAs are highly stable and consistent among individuals of the same species. Specific miRNA expression signatures in extracellular environment have been identified in a variety of human diseases, including cancer and neurological diseases, revealing the diagnostic potential of circulating miRNAs as useful non-invasive biomarkers ([@B1]; [@B18]; [@B88]).

Several *in vitro* studies have shown that miRNAs transferred by the different types of carriers are functional and can regulate gene expression in recipient cells.

Apoptotic bodies generated from endothelial cells during atherosclerosis were shown to contain miR-126, which controls endothelial cell signaling *in vitro* and provides atheroprotective effects *in vivo* ([@B89]).

Another study showed that endothelial cells can transfer functional miR-143 and miR-145 to smooth muscle cells where they mediate the reduction of atherosclerotic lesion formation *in vivo* ([@B27]).

Similarly, circulating miR-150 is released by monocytes and taken up by endothelial cells where it regulates endothelial cell migration ([@B90]).

Although the complete mechanism of gene regulation mediated by specifically selected extracellular circulating miRNAs has yet to be clearly demonstrated *in vivo*, these studies suggest a plausible form of cell-to-cell communication in which donor cells send their miRNAs to distant recipient cells where they exert their regulatory functions.

VIRUSES EXPLOIT EXTRACELLULAR PARTICLES TO ESTABLISH AND MAINTAIN THE INFECTION
-------------------------------------------------------------------------------

It has been shown that some viruses exploit extracellular particles, such as microvesicles, for the initiation and progression of the infection ([@B51]). According to the trojan exosome hypothesis proposed by [@B23], retroviruses may use the pre-existing non-viral exosome biogenesis and uptake pathways for the formation, release, and delivery of viral particles.

This has been later supported by evidence that some viruses utilize endosomal compartments of the host to generate exosome-like vesicles ([@B29]) which can play different roles in the infection, contributing to its spreading ([@B48]), favoring exosomal biogenesis ([@B12]), and providing immune evasion ([@B77]).

Viral exosomes, for instance, affect the host immune system in different ways according to the type of virus and the stage of its life cycle in which exosome secretion occurs in the infected host. As proving example, during the non-replicative stage, dendritic cells serve as transit location for HIV-1 (human immunodeficiency virus 1) which exploits their intracellular vesicle trafficking pathways to release antigens and viral particles into the extracellular space and *trans*-infect CD4+ T cells ([@B35]).

Generally, viruses implement different strategies during infection essentially consisting in escaping the host immune system and facilitating the invasion and proliferation within the host. Observations suggest that the release of microvesicles containing specific cellular and viral components by infected cells contributes greatly to the preservation of the virus even in a hostile antiviral immune environment ([@B13]; [@B34]; [@B44]; [@B25]; [@B51]).

Epstein--Barr virus (EBV), cytomegalovirus (CMV), and hepatitis C virus (HCV) have found means to evade immune responses and increase virus-fusing ability and infectivity by exploiting microvesicles, giving rise to a systematic distribution of viral agents from infected cells able to induce genetic and epigenetic modifications in recipient cells ([@B50]; [@B44]; [@B63]; [@B86]).

Tumor-associated viruses, like EBV, may use exosomal transfer to manipulate the growth characteristics of neighboring cells and enhance tumor progression. In particular, exosomes released from nasopharingeal carcinoma (NPC) cells harboring latent EBV were shown to contain the EBV latent membrane protein 1 (LMP1; [@B52]), which is frequently expressed in EBV-associated cancers and has potent effects on cell growth by inducing growth-stimulating signaling pathways ([@B84]; [@B38]) and may modulate the selective sorting of proteins into exosomes, favoring important signaling molecules frequently activated in cancers such as phosphatidylinositol 3-kinase (PI3K) and epidermal growth factor receptor (EGFR; [@B52]).

VIRUSES ENCODE miRNAs
---------------------

RNA interference (RNAi) most probably was originally selected as a primary mechanism of defense against harmful genetic elements such as viruses. It is of relevant interest that in the evolutionary selection this mechanism was in turn exploited by viruses to their advantage while, as suggested by [@B78], chordate use of small RNAs might exclusively have shifted to the silencing of genome-encoded transcripts and would at least not pose direct threat to RNA viral genome.

The first report of viral-encoded miRNAs was published by [@B61] describing the cloning of viral miRNAs from cells infected with EBV. Among DNA viruses, which account for the majority of known virus-encoded miRNAs, 95% of viral miRNAs known today are of herpesvirus origin.

The majority of natural viruses found to encode miRNAs have thus a DNA component to their replication cycle, can exploit the initiating host miRNA biogenesis machinery in the nucleus where they replicate, and cause long-term persistent infections. DNA viruses such as the ones belonging to the Herpesvirus, Polyomavirus, Ascovirus, Baculovirus, Iridovirus, and Adenovirus families clearly match these characteristics ([@B74]; [@B22]; [@B9]; [@B33]; [@B68]; [@B69]; [@B4]; [@B49]; [@B72]; [@B91]; [@B46]) along with at least one member of the retrovirus family, bovine leukemia virus (BLV), which clearly encodes numerous miRNAs ([@B41]).

Despite the established case of BLV, viruses possessing positive or negative sense RNA or double-stranded RNA (dsRNA) genome are not widely accepted to naturally express miRNAs.

Nevertheless, HIV-1 has been proven to encode two miRNAs and potentially a third. In fact, hiv1-mir-H1 was proven to be responsible for inducing apoptosis and repressing host gene expression ([@B37]), while hiv-1-miR-N367 has been suggested as functional ortholog of hsa-miR192 ([@B87]). Finally, some evidence is present that the HIV-1 TAR element could be a potential viral miRNA ([@B30]), also considering its capability to target pro-apoptotic genes ([@B43]).

All viral miRNAs can essentially be grouped into two classes: host analogs and virus-specific. Generally, though, their functions include prolonging longevity of infected cells, evading the immune response, and regulating host or viral genes to limit the lytic cycle. Interestingly, all these functions are essential for infections to be persistent.

In fact, miRNAs are likely invisible to the adaptive immune system -- a valuable trait for viruses that undergo persistent infection ([@B11]). Thus, in viruses that establish a long-lasting latent infection, such as herpesviruses, one important benefit they could gain from employing miRNAs is the ability to regulate host and/or viral gene expression without having to elicit an antigenic immune reaction or directly suppressing components of the host immune system ([@B73]).

Preventing cell death seems an obvious advantage to viruses that cause persistent or latent infections. Several different viruses including Kaposi's sarcoma-associated herpesvirus (KSHV), EBV, and Marek's Disease Virus type 1 (MDV1) encode miRNAs that can play a subtle role in preventing apoptosis by targeting pro-apoptotic host genes and are also associated with tumorigenesis.

PERSPECTIVES
============

VIRUSES CAN USE VESICLES TO EXPORT THEIR FUNCTIONAL miRNAs
----------------------------------------------------------

[@B60] were the first ones (and, to our knowledge, the only ones together with [@B52]) to have demonstrated that virus-infected cells package virus-encoded RNAs, and specifically viral miRNAs, into exosomes which are exported into the extracellular space and eventually delivered to recipient, non-infected cells, favoring the repression of specifically important mRNA targets. EBV is a clear example of a virus that utilizes the exosome pathway for the selective secretion of viral and cellular proteins and miRNAs that likely participate in cell-to-cell communication in the absence of virus production, potentially modulating cell function.

As confirming proof, [@B60] reported that EBV-infected activated B cells secrete exosomes containing viral miRNAs shown to be delivered and actively internalized by monocyte-derived dendritic cells in co-culture. In particular, the copy number of EBV-miRNA BART1-5p was consistently higher than other EBV-miRNAs and its level increased fourfold after additional 24 h co-culture. This resulted in a dose-dependent, miRNA-mediated repression of confirmed EBV target genes. More specifically, the viral miRNA BHRF1-3 was shown to suppress the expression of the immunostimulatory gene CXCL11 \[Chemokine (C-X-C motif) ligand 11\] and this repression was proven to be dependent on the amount of exosomes carrying the miRNA and was not recipient cell-type-specific. In addition, expression of EBV-miRNAs in EBV-infected circulating B cells was also investigated. The data collected suggested that in asymptomatic patients BART miRNAs are expressed by latently infected circulating B cells as well as present in non-infected non-B cells, supporting the possibility of miRNA transfer *in vivo*. This further supported the proposal that exosomes could most likely serve as deliverers of small RNA due to their specialized biogenesis and presumed entry route ([@B93]).

Later evidence showed that EBV-encoded miRNAs have been detected in exosomes from EBV-infected NPC cells, together with the LMP1 protein and other signal transduction molecules ([@B52]), in accordance to other studies proving the presence of cellular miRNAs in tumor-derived exosomes ([@B76]; [@B39]; [@B59]).

Furthermore, differences detected in the levels of intracellular and exosomial miRNAs, in addition to differences even in the amount of enrichment between the individual exosomal miRNAs, suggest that some viral miRNAs might be specifically intended and selected to be packaged into exosomes and exert their functions in cells other than those producing them ([@B44]; [@B52]; [@B60]). Moreover, exosomes may also deliver cellular components of the RNA-induced silencing complex (RISC) to enhance viral miRNA function ([@B21]).

These results were greatly motivated by the assumption that exosomal exportation of miRNAs in general may have a fundamental role in intercellular communication despite the lack of concrete evidence ([@B81]; [@B70]; [@B79]).

Although functional significance of all these phenomena requires further investigation, these results suggest that a cellular miRNA-loading mechanism may exist to direct specific miRNAs into intraluminal vesicles of multivesicular endosomes (MVEs) which could explain why exogenous exosomal miRNAs are capable of repressing targets in recipient cells at new subcellular compartments for RNAi activity such as late endosomes ([@B55]; [@B71]; [@B21]). **Figure [1](#F1){ref-type="fig"}** depicts all the potential ways in which viruses could exploit extracellular particles to convey their miRNAs to non-infected recipient cells.

![**Summary model of plausible mechanisms for export and functional delivery of viral miRNAs.** The image depicts the possible means of transcription, packaging, and functional delivery of viral miRNAs during an infection. Virus-encoded miRNAs are transcribed by the infected cell **(A)**. They could exploit various channels to reach extracellular space and, eventually, be delivered to recipient non-infected cells: inside apoptotic bodies after cell death **(B)**, packaged into exosomes **(C)**, or HDL/LDL molecules or even bound to AGO2 **(D)**. Viral miRNAs may be uptaken by non-infected cells where they could exert their regulatory functions **(E)**.](fgene-04-00120-g001){#F1}

FUNCTIONAL ANALYSIS OF CIRCULATING VIRAL miRNAs
-----------------------------------------------

The correct identification of targets is fundamental to determine miRNA function. Computational miRNA target prediction is still a big challenge, mostly due to the fact that our knowledge about the mechanisms and the molecular rules of miRNA target recognition is still incomplete ([@B3]). Nevertheless, there are many computational tools available online, which allow to identify the most probable miRNA targets and to uncover non-trivial relationships between miRNAs and other molecular actors ([@B7]). These tools collect and integrate heterogeneous miRNA-related data retrieved from different sources, such as target prediction tools and expression profiles of miRNAs and mRNAs, in order to infer miRNA functions and produce general models of miRNA-mediated regulation in the context of complex processes. Few tools are available specifically for the analysis of viral miRNAs and they are limited to the prediction of new miRNAs and targets. RepTar and vHoT are databases of predicted interspecies interactions between viral miRNA and host genomes, while ViTa is a database containing predictions of host miRNA targets on viruses ([@B31]; [@B16]; [@B40]). miRiam is a software that has been used to predict potential human targets for viral miRNAs ([@B45]). Finally, VMir and Vir-Mir are tools for the prediction of novel virus-encoded miRNAs ([@B47]; [@B24]). In regard to functional analysis, despite the lack of specific programs for viral miRNAs, general miRNA tools can be successfully applied to the study of viral miRNAs as well. A very recent study shows that the predicted targets of the 135 known viral miRNAs in human viruses and of 6809 putative miRNAs encoded by 23 human viruses, as predicted by Vir-Mir, are enriched for specific host pathways whose targeting is likely beneficial to the virus, such as cancer, axon guidance, ErbB, mitogen-activated protein kinase (MAPK), and wingless-type MMTV integration site family (Wnt) signaling ([@B6]). The authors performed a functional enrichment analysis by comparing each gene target set with an annotated functional gene set corresponding to KEGG (Kyoto Encyclopedia of Genes and Genomes) pathways and Gene Ontology biological processes. As further proof of principle, we used miRiam to predict the potential targets of EBV miRNAs in which exosomes are particularly enriched, as reported by [@B60] (miR-BHRF1-1/1-2-3p and miR-BART1-3p/5p/-2-3p). Then, we used the tool ingenuity pathway analysis (IPA) to perform a functional enrichment analysis of the predicted targets (<http://www.ingenuity.com>). The results show that subsets of the targets are significantly involved in cancer pathways, in particular leiomyomatosis, and mesenchymal tumors, for which a connection with EBV had already been described ([@B8]; [@B54]; [@B14]; [@B75]). Other significant pathways include WNT/B-catenin signaling, interleukin 8 (IL-8) signaling, and P53 pathway (*P* \< 0.0001), also previously described as related to EBV infections ([@B56]; [@B17]; [@B66]; [@B85]; [@B19]; [@B32]; [@B64]). The predicted targets are also enriched in GO terms such as cell death and survival and cell cycle (*P* \< 0.04). Furthermore, although the significance of the *P*-value is borderline (*P* \< 0.4), it is worth to mention that the top tox functions reported by IPA include increased levels of alkaline phosphatase and LDH, tumour-marker characteristics which have been reported to be significant prognostic factors in metastatic NPC, often associated wih EBV infection ([@B36]). **Table [1](#T1){ref-type="table"}** summarizes the most significant associations.

###### 

Functional enrichment analysis of circulating EBV miRNAs' predicted targets.

                                                                   *P*-Value
  ---------------------------------------------------------------- -----------------
  **Selected canonical pathways**                                  
  Molecular mechanisms of cancer                                   5.27 × 10^-11^
  PPARα/RXRα activation                                            9.39 × 10^-6^
  Wnt/β-catenin signaling                                          1.25 × 10^-5^
  p53 signaling                                                    6.73 × 10^-5^
  IL-8 signaling                                                   1.56 × 10^-4^
  **Selected molecular and cellular functions**                    
  Cell morphology                                                  \<3.6 × 10^-2^
  Cell death and survival                                          \<3.72 × 10^-2^
  Cell cycle                                                       \<4.09 × 10^-2^
  **Selected diseases and disorders: cancer**                      
  Leiomyomatosis                                                   1.21 × 10^-5^
  Cell transformation                                              2.60 × 10^-3^
  Growth of tumor                                                  5.14 × 10^-3^
  Mesenchymal tumor                                                8.31 × 10^-3^
  **Selected tox functions (Clinical Chemistry and Hematology)**   
  Decreased levels of albumin                                      1.37 × 10^-1^
  Increased levels of alkaline phosphatase                         2.21 × 10^-1^
  Increased levels of albumin                                      3.70 × 10^-1^
  Increased levels of LDH                                          3.70 × 10^-1^

The table summarizes the most relevant results, particularly associated to EBV infection, of the functional analysis conducted using the software IPA. Results are organized in categories. For each category, the most significant terms, together with their

P

-Values, are displayed. EBV-encoded miRNAs in which exosomes are particularly enriched were selected (miR-BHRF1-1/1-2-3p and miR-BART1-3p/5p/-2-3p) and their targets predicted using the tool miRiam. The top scoring targets were given as input to IPA.

These few examples clearly indicate that miRNA functional analysis tools can be of great help in studying the effects of circulating viral miRNAs, allowing the production of plausible hypotheses about their function and involvement in crucial cellular pathways, encouraging the development of more specific tools for computational investigation of cellular and extracellular viral miRNA.
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